<span item_type="fundamental" item_id="02d20662ac76346aaf8739d39bd46d2a" counter_id="ST/US/OCEAW" env="prod"></span><span item_type="announcement" item_id="516484277211236481" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.09.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of products in the foreseeable future.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $8.2 million for the three months ended March 31, 2025, compared to a net income of $13.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li><li><strong>Operating Loss</strong>: Operating loss for the three months ended March 31, 2025 was $958,000, compared to $595,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased by $0.4 million to $940,000 for the three months ended March 31, 2025, primarily due to increased costs associated with the year-end audit and filing of Form 10-K.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $356,000 for the three months ended March 31, 2025, compared to - $485,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $909,000 for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Backstop Put Option Liability</strong>: Valued at - $61,411,000 as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li><li><strong>Fixed Maturity Consideration</strong>: Valued at - $6,002,000 as of March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to advance preclinical development of its early-stage programs and manufacture preclinical and clinical drug material.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is considering entering into collaborations or other arrangements to obtain additional funding, which is critical for its operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li>The company emphasizes the need for additional capital to fund operations into the third quarter of 2025 and is exploring various funding options, including private equity financings and debt financings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm"></span></li></ul>

OCEAN BIOMEDICAL INC C/WTS 14/02/2028 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.09